Abingworth

Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciences sectors.

Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park, and Boston, Abingworth has invested in 142 life science companies, completed 60 IPOs and 40 mergers and acquisitions.

Abingworth, established in 1973 and headquartered in Europe., specializes in Early Stage Venture, Late Stage Venture, Private Equity, Seed investments across Biotechnology, Health Care, Medical, Medical Device, Financial Services, Venture Capital, Finance, Therapeutics, Life Science, Social. The organization boasts a portfolio of 181 investments, with an average round size of $47.0M and 84 successful exits. Their recent investments include Broncus Technologies, Menlo Ventures, HBM Healthcare Investments, Synosia Therapeutics, Versant Ventures. The highest investment round they participated in was $786.9B. Among their most notable exits are Broncus Technologies and Menlo Ventures. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.